Although experts agree that in the care of patients struggling with hemato-oncologic diseases such as chronic lymphocytic leukemia and plasmocytic myeloma, we have a standard of treatment largely in line with Western standards, the results of treatment are still not entirely satisfactory. Data from the National Cancer Registry show that survival in Poland is still 10 percent lower than in Western European countries.
Meanwhile, we can talk about a breakthrough that has been made in the treatment of PBL. This is a therapy using two groups of drugs: Bruton's kinase inhibitors such as acalabrutinib, zanubrutinib and ibrutinib. All of these drugs are reimbursed in Poland. An alternative therapy is venetoclax in combination with obinutosumab, also reimbursed for first-line treatment.
- We are missing a single therapeutic regimen that combines two innovative drugs: ibrutinib and venetoclax. This is a very interesting regimen, because it combines two innovative drugs, and this therapy is interesting in that it is a time-limited therapy. Bruton's kinase inhibitor therapy lasts for many years. Most people will receive...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
